Alx Oncology Holdings (ALXO) Revenue (2019 - 2020)
Alx Oncology Holdings (ALXO) reported Revenue of $527000.0 for Q2 2020, down 59.31% on a YoY basis from $1.3 million in Q3 2019, and down 19.54% sequentially from $655000.0 in Q1 2020.
Alx Oncology Holdings (ALXO) Revenue (2019 - 2020) Analysis & Trends
Alx Oncology Holdings (ALXO) has 2 years of Revenue data on file, last reported at $527000.0 in Q2 2020.
- For the quarter ending Q2 2020, Revenue fell 59.31% year-over-year to $527000.0; the trailing twelve-month figure through Mar 2021 stood at $527000.0 (down 88.07% YoY), and the FY2020 full-year result was $1.2 million, down 75.35% from the prior year.
- Revenue slipped to $527000.0 in Q2 2020, from $655000.0 in the prior quarter.
- In the past five years, Revenue ranged from a high of $1.3 million in Q2 2019 to a low of $527000.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 1.30 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alx Oncology Holdings | 213.33 Mn | 213.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 527,000.00 |
| Mar 31, 2020 | 655,000.00 |
| Dec 31, 2019 | 1.21 Mn |
| Sep 30, 2019 | 1.26 Mn |
| Jun 30, 2019 | 1.30 Mn |